Checkpoint Kinase Inhibitors - Pipeline Insight, 2025

This “Checkpoint kinase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Checkpoint kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Checkpoint kinase inhibitors Understanding

Checkpoint kinase inhibitors: Overview

Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. The checkpoint kinases, Chk1 and Chk2 are Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is repaired. The development of checkpoint kinase inhibitors for the treatment of cancer has been a major objective in drug discovery. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. The majority of CHK1 inhibitors are ATP competitive and bind directly to the hinge peptide region found between the N- and C-terminal lobes of the kinase domain. Checkpoint kinase inhibitors offer the promise of enhancing the effectiveness of widely prescribed cancer chemotherapies and radiotherapy by inhibiting the DNA damage response, as well as the potential for single agent efficacy. Due to their potential application as novel anticancer therapies, inhibitors of CHK1 and CHK2 have become the focus of numerous drug discovery projects.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint kinase inhibitors R&D. The therapies under development are focused on novel approaches for Checkpoint kinase inhibitors.

Checkpoint kinase inhibitors Emerging Drugs Chapters

This segment of the Checkpoint kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Checkpoint kinase inhibitors Emerging Drugs

BI 765063: Boehringer Ingelheim

BI 765063 (OSE-172) is a monoclonal antibody, SIRPα an antagonist and first-in-class myeloid checkpoint inhibitor which selectively inhibits SIRPα thus restoring TAM and dendritic cells’ activity in response to tumors. Boehringer Ingelheim is evaluating the potential drug in Phase 1 clinical trial in patients with advanced solid tumors.

CBP501: CanBas

CBP501 is a peptide mimetic for the treatment of solid tumors. CBP501 is a version of TAT-S216A optimized for its G2 checkpoint abrogating activity by using a cell cycle phenotype-based screening method, proprietary to CanBas. CBP501 enhance the inhibition of tumor growth by cisplatin, carboplatin, or bleomycin in vivo in a variety of mouse tumor xenograft models without significant adverse effects, but CBP501 also enhances the efficacy of several immune checkpoint inhibitors when these are used in combination with cisplatin or carboplatin. The drug is currently in Phase Ib clinical evaluation for the treatment of Advanced Refractory Tumors.

Checkpoint kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Checkpoint kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Checkpoint kinase inhibitors

There are approx. 15+ key companies which are developing the Checkpoint kinase inhibitors. The companies which have their Checkpoint kinase inhibitors drug candidates in the most advanced stage, i.e. Registration include, GlaxoSmithKline.

Phases

The report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Checkpoint kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Checkpoint kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Checkpoint kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Checkpoint kinase inhibitors drugs.

Checkpoint kinase inhibitors Report Insights

• Checkpoint kinase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Checkpoint kinase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Checkpoint kinase inhibitors drugs?
• How many Checkpoint kinase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Checkpoint kinase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Checkpoint kinase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Checkpoint kinase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• CanBas
• Vernalis
• Sierra Oncology
• Pharos I&BT Co
• Array BioPharma
• Eli Lilly and Company
• Sentinel Oncology
• BriaCell Therapeutics
• IMPACT Therapeutics
• Pink Biopharma

Key Products

• BI 765063
• CBP501
• VER-250840
• SRA737 Sierra Oncology
• PHI-101
• Prexasertib
• SOL 578
• Research program: anticancer therapeutics
• IMP 10
• Research Program: checkpoint kinase inhibitors

This product will be delivered within 2 business days.